ImmuPharma Plc has announced that it has raised gross proceeds of £130,683 through the issue of 6,534,150 new ordinary shares at a price of 2 pence to existing retail investors of the company. This is in addition to the £1.35 million raised in the Subscription and Direct Subscription. The new ordinary shares will be admitted to trading on AIM and dealings are expected to commence on or around September 12, 2023. Director Lisa Baderoon subscribed for 1,000,000 retail offer shares in the retail offer, bringing her shareholding to 1,583,963 ordinary shares, representing 0.38% of the issued share capital. After the admission, the company will have 416,437,265 ordinary shares in issue.